Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,851.50    31.00 (1.70%)
Bid:
1,851.50
Ask:
1,852.00
Spread: 0.50 (0.027%)
Market Cap: £74.25b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Result of AGM

7 May 2025 18:22

RNS Number : 7755H
GSK PLC
07 May 2025
 

GSK plc

 

Results of 25th Annual General Meeting

 

GSK plc ('GSK') held a hybrid Annual General Meeting ('AGM') at 2.30pm on Wednesday 7 May 2025 at The Landmark London, 222 Marylebone Road, London, NW1 6JQ. Shareholders were able to join the meeting in person or virtually via the Lumi AGM website and Zoom.

 

All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.

 

All 25 resolutions were passed and decided upon by a poll. The table below shows the results for each resolution. The full text of the resolutions is contained in the Notice of AGM published on 24 March 2025, which is available on GSK's website at www.gsk.com.

 

Resolution

Total votes for(1)(2)

%

Total votes against(2)

%

Total votes cast

% of Issued Share Capital voted(3)

Votes withheld(4)

1

Receive and adopt the 2024 Annual Report

3,031,647,740

99.82

5,472,209

0.18

3,037,119,949

73.91%

12,204,390

2

Approve the Annual report on remuneration 

2,810,183,626

92.46

229,176,108

7.54

3,039,359,734

73.97%

9,979,421

3

Approve the Remuneration policy

2,786,567,742

93.10

206,384,696

6.90

2,992,952,438

72.84%

56,376,703

4

Election of Dr Gavin Screaton

3,040,206,238

99.89

3,385,136

0.11

3,043,591,374

74.07%

5,719,426

5

Re-election of Sir Jonathan Symonds

2,947,917,394

98.40

48,075,530

1.60

2,995,992,924

72.91%

53,319,043

6

Re-election of Dame Emma Walmsley

3,038,248,728

99.82

5,613,533

0.18

3,043,862,261

74.08%

5,444,311

7

Re-election of Julie Brown

3,034,344,765

99.69

9,515,889

0.31

3,043,860,654

74.08%

5,460,463

8

Re-election of Elizabeth McKee Anderson

2,941,679,748

96.64

102,161,424

3.36

3,043,841,172

74.08%

5,465,676

9

Re-election of Charles Bancroft

2,956,308,387

97.13

87,450,752

2.87

3,043,759,139

74.07%

5,553,709

10

Re-election of Dr Hal Barron

3,039,339,475

99.85

4,466,176

0.15

3,043,805,651

74.08%

5,489,801

11

Re-election of Dr Anne Beal

2,955,431,838

97.09

88,492,673

2.91

3,043,924,511

74.08%

5,388,566

12

Re-election of Wendy Becker

2,933,164,994

96.36

110,745,350

3.64

3,043,910,344

74.08%

5,400,009

13

Re-election of Dr Harry C Dietz

3,039,383,688

99.86

4,369,000

0.14

3,043,752,688

74.07%

5,560,851

14

Re-election of Dr Jeannie Lee

3,039,577,387

99.86

4,161,377

0.14

3,043,738,764

74.07%

5,574,652

15

Re-election of Dr Vishal Sikka

3,038,858,707

99.84

4,756,490

0.16

3,043,615,197

74.07%

5,688,803

16

Re-appointment of the auditor

3,025,673,462

99.89

3,223,574

0.11

3,028,897,036

73.71%

20,430,064

17

Remuneration of the auditor

3,039,931,435

99.88

3,782,302

0.12

3,043,713,737

74.07%

5,591,584

18

Authority for the company to make donations to political organisations and incur political expenditure

2,946,755,927

99.01

29,581,561

0.99

2,976,337,488

72.43%

72,977,673

19

Authority to allot shares

2,899,903,495

95.30

143,133,156

4.70

3,043,036,651

74.06%

6,282,441

20

Disapplication of pre-emption rights - general power(5)

2,941,521,597

96.72

99,811,731

3.28

3,041,333,328

74.02%

7,942,085

21

Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment(5)

2,962,038,875

97.39

79,351,038

2.61

3,041,389,913

74.02%

7,904,048

22

Authority for the company to purchase its own shares(5)

3,036,538,826

99.83

5,280,936

0.17

3,041,819,762

74.03%

7,499,989

23

Exemption from statement of senior statutory auditor's name

3,022,840,749

99.74

7,951,051

0.26

3,030,791,800

73.76%

18,502,136

24

Authority for reduced notice of a general meeting other than an AGM(5)

2,863,892,275

94.11

179,242,127

5.89

3,043,134,402

74.06%

6,172,307

25

Approve the adoption of the GSK Share Value Plan

2,972,805,515

99.56

13,033,137

0.44

2,985,838,652

72.67%

63,503,752

 

 

Notes:

 

(1) The "for" votes include those giving the Chair discretion.

(2) Votes "for" and "against" are expressed as a percentage of the total votes cast.

(3) The Company's issued share capital as at 2 May 2025 consisted of 4,109,037,095 shares of 31 ¼ pence each ('Ordinary Shares') excluding Ordinary Shares held in Treasury. Every shareholder has one vote for every Ordinary Share held.

(4) A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.

(5) Indicates Special Resolutions requiring a 75% majority of votes cast.

 

 

The following table provides further information on participation in the AGM:

 

 

GSK's 25th AGM

(Hybrid meeting)

(2025)

GSK's 24th AGM

(Hybrid meeting)

(2024)

Issued share capital (excluding Treasury Shares)

4,109,037,095

 

4,314,108,510

Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)

74.21%

73.11%

Total shareholder population

86,241

60,448

Total number of proxies lodged

3,743

2,886

Number of shareholders in attendance

130 in person

25 participated virtually

125 in person

38 participated virtually

% of shareholders who lodged proxies

4.34%

4.77%

 

 

The above poll results will shortly be available on the company's website at www.gsk.com.

 

In accordance with Listing Rule 6.4.2 of the Financial Conduct Authority's (FCA) Listing Rules, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the FCA and will, in due course, be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

 

 

V A Whyte

Company Secretary

7 May 2025

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGARMRTMTTMBBA
Date   Source Headline
22nd Dec 20257:00 amRNSGSK to lower drug prices and expand access in US
22nd Dec 20257:00 amRNSGSK to lower drug prices and expand access in US
22nd Dec 20257:00 amRNSTransaction in Own Shares
22nd Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
18th Dec 20257:00 amRNSTransaction in Own Shares
17th Dec 20257:00 amRNSExdensur (depemokimab ulla) approved by US FDA
17th Dec 20257:00 amRNSTransaction in Own Shares
16th Dec 20257:00 amRNSExdensur (depemokimab) UK MHRA approval
16th Dec 20257:00 amRNSTransaction in Own Shares
15th Dec 20257:00 amRNSTransaction in Own Shares
12th Dec 20251:50 pmRNSNucala receives positive CHMP opinion for COPD
12th Dec 20251:41 pmRNSDepemokimab receives positive CHMP opinion
12th Dec 20257:00 amRNSPositive CHMP opinion on Arexvy for all adults 18+
12th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:54 pmRNSBlujepa approved in US for gonorrhoea indication
11th Dec 20253:30 pmRNSDirector/PDMR Shareholding
11th Dec 20259:00 amRNSBlock Listing Application
11th Dec 20257:00 amRNSTransaction in Own Shares
10th Dec 20257:00 amRNSGSK'227 US FDA Orphan Drug Designation in SCLC
10th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20253:30 pmRNSDirector/PDMR Shareholding
9th Dec 20257:00 amRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
5th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20253:30 pmRNSDirector/PDMR Shareholding
1st Dec 20253:00 pmRNSTotal Voting Rights
1st Dec 20257:00 amRNSTransaction in Own Shares
28th Nov 20257:00 amRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSTransaction in Own Shares
25th Nov 20257:00 amRNSTransaction in Own Shares
24th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSInitiation of litigation against AnaptysBio Inc
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
19th Nov 20257:15 amRNSTransfer of Treasury Shares
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20253:30 pmRNSDirector/PDMR Shareholding
18th Nov 20257:00 amRNSTransaction in Own Shares
17th Nov 20257:00 amRNSTransaction in Own Shares
14th Nov 20257:00 amRNSTransaction in Own Shares
13th Nov 20253:30 pmRNSDirector/PDMR Shareholding
13th Nov 20257:00 amRNSTransaction in Own Shares
12th Nov 20253:30 pmRNSBlock listing Interim Review
12th Nov 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.